Shire Extends RegenMed Reach in $200M Pervasis Acquisition

Having trouble viewing images? View in web browser BIOTECH'S MOST RESPECTED NEWS SOURCE FOR MORE THAN 20 YEARS

Shire Extends RegenMed Reach In $200M Pervasis Acquisition By Marie Powers Staff Writer Shire plc pumped up its regenerative medicine business by acquiring all but the oncology assets of privately held Pervasis Therapeutics Inc., which is developing an endothelial cell-based technology, in a deal valued at up to $200 million. Shire, of Dublin, Ireland, will make an undisclosed upfront payment plus potential milestone payments predicated on the achievement of clinical development, regulatory and sales targets. “We like these kinds of success-based, share-the-risk deals,” said Kevin Rakin, CEO of Advanced BioHealing (ABH), the regenerative medicine fi rm Shire acquired last year and operates as a separate business unit. The price tag is a fraction of the $750 million cash deal for ABH, which set the large pharma’s regenerative medicine business in motion. Click here to read the issue featuring this article »	Personalized Medicine Evolves: Biz Hurdles Rival Technical By Trista Morrison Staff Writer SAN DIEGO – Despite the imminent arrival of the $1 ,000 genome, several technical and business hurdles must be overcome to move personalized medicine into the mainstream, according to two recent panels hosted by the San Diego Venture Group and Southern California life sciences industry organization BIOCOM. David Nelson, president and CEO of companion diagnostics fi rm Epic Sciences Inc., noted that the drug industry inhabits “a world of technical risk,” with nine out of 10 drugs failing to reach the market. Personalized medicine will reduce that risk dramatically, he said, pointing to how a companion diagnostic helped Pfi zer Inc.’s targeted lung cancer drug Xalkori (crizotinib) advance through the clinic quickly, with replicable data and no surprises as the patient pool expanded. Click here to read the issue featuring this article »
Lung Site of Leukocyte Entry Translates into COPD Insight By Anette Breindl Science Editor Scientists from the University of California, Davis, have gained new insights into the initial phase of chronic obstructive pulmonary disease (COPD), which kills about 3 million people a year in the U.S. “Our discovery,” corresponding author Ben Davis told BioWorld Today, “helps us better understand how the disease begins, the pattern of the disease and how to design better COPD drugs.” Smoking, which is responsible for 80 percent of COPD cases, causes inflammatory white blood cells called leukocytes to flock to the lung, where they damage the lung by releasing several enzymes that contribute to the development of COPD. Click here to read the issue featuring this article »	Algeta Opts for 50-50 Split In Bayer Deal for Alpharadin By Nuala Moran Staff Writer LONDON – Algeta ASA has decided to go for the higher-risk, but hopefully more profi table route in U.S. commercialization of Alpharadin, exercising an option on a 50-50 co-promotion agreement for which it is liable for half the costs. Under a September 2009 global licensing deal with partner Bayer AG, Algeta had the right either to receive a royalty on sales or to take ascending co-promotion rights – from 25 percent up to a maximum of half the market – for Alpharadin, radium-223 chloride for treating bone metastases. “We’ve taken the full 50 percent because this is an area of such high medical need,” CEO Andrew Kay told BioWorld Today. “This is a major step forward for Algeta – we are making a blockbuster investment in what everyone says will be a blockbuster drug.” Click here to read the issue featuring this article »

Thompson Publishing Group | 805 15th Street, NW, 3rd Floor | Washington, DC 20005 | service@thompson.com | © 2011 Thompson Publishing Group. All rights reserved. You are receiving this email because you previously purchased products or indicated you wanted to be informed of the latest news and specials from Thompson Publishing Group. This is an advertising email. This message was intended for: {{lead.Email Address:default=email}}. You can manage your subscription here or if you prefer not to receive future emails from Thompson, you can unsubscribe here.

You have received this email because you registered at BioSpace. BioSpace regularly sends emails to active subscribers on behalf of our advertising partners or to promote our own products and services. If you would like to stop receiving all email communications from BioSpace, you can unsubscribe at any time by clicking here. BioSpace 6465 South Greenwood Plaza, Suite 400, Centennial, CO 80111, U.S. (888) BIOSPACE